Abstract
Measles virus (MV) is an infectious disease related to thousands of deaths in previous outbreaks. Health agencies estimated that approximately 42% of countries would have the eradication of this pathogen. However, the virus remains as a challenging health problem for countries’ economies. This pathogen is highly transmissible via the respiratory droplets of infected individuals, which remain in the air and surfaces for several hours, increasing its rate of transmission. Prophylactic vaccination is the most effective strategy in controlling this infection. In recent years, political-economic factors and the anti-vaccine movement have contributed to its reemergence. Despite apparently being a controlled disease, these factors contributed to the increase in the number of cases, including fatalities. Also, there is still no drug used in the disease’s clinical management, justifying the investment in new alternatives. This chapter will be addressed to the main advances in new therapies against MV, highlighting hit compounds, focusing on non- and nucleoside, peptide, quinoline, retinoid analogs, and other derivatives. Besides the main advances in biological approaches such as glycosaminoglycan and interferon; also immunological approaches exist such as plant-and peptide-based vaccines. Nucleoside and non-nucleoside analogs are the most explored chemical agents, resulting in several promising molecules. Also, natural products could be effective in controlling MV. Finally, advances in immunological strategies, such as discovering new vaccines show that (despite a vaccine’s existence) it is necessary to find another more effective and accepted by the population, leading to the definitive eradication of this disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arendt F, Scherr S. Social science & medicine news-stimulated public-attention dynamics and vaccination coverage during a measles outbreak : an observational study. Soc Sci Med. 2020:113495. https://doi.org/10.1016/j.socscimed.2020.113495.
Ashkenazi S, Livni G, Klein A, Kremer N, Havlin A, Berkowitz O. The relationship between parental source of information and knowledge about measles/measles vaccine and vaccine hesitancy. Vaccine. 2020;38:7292–8. https://doi.org/10.1016/j.vaccine.2020.09.044.
Azegami T, Yuki Y, Kiyono H. Plant-based mucosal vaccine delivery systems. Mucosal Vaccines Innov Prev Infect Dis. 2019:357–70. https://doi.org/10.1016/B978-0-12-811924-2.00020-1.
Baker JP. The first measles vaccine. Pediatrics. 2011;128:435–7. https://doi.org/10.1542/peds.2011-1430.
Barnard DL. Inhibitors of measles virus. Antivir Chem Chemother. 2004;15:111–9. https://doi.org/10.1177/095632020401500301.
Barnard DL, Stowell VD, Seley KL, Hegde VR, Das SR, Rajappan VP, et al. Inhibition of measles virus replication by 5′-Nor carbocyclic adenosine analogues. Antivir Chem Chemother. 2001;12:241–50. https://doi.org/10.1177/095632020101200405.
Beare A, Bynoe ML, Tyrrell DA. Prophylaxis of influenza with a synthetic isoquinoline. Lancet. 1968;20:843–5.
Benecke O, DeYoung SE. Anti-vaccine decision-making and measles resurgence in the United States. Glob Pediatr Heal. 2019;6:2333794X1986294. https://doi.org/10.1177/2333794x19862949.
Bonneton M, Antona D, Danis K, Aït-Belghiti F, Levy-Bruhl D. Are vaccinated measles cases protected against severe disease? Vaccine. 2020;38:4516–9. https://doi.org/10.1016/j.vaccine.2020.05.005.
Braun E, Hotter D, Koepke L, Fackler OT, Kirchhoff F, Sauter D, et al. Antiviral activity by inhibiting furin-mediated processing of viral envelope proteins guanylate-binding proteins 2 and 5 exert broad antiviral activity by inhibiting furin-mediated processing of viral envelope proteins 2019:2092–104.
Brown DW, Warrener L, Scobie HM, Donadel M, Waku-Kouomou D, Mulders MN, et al. Rapid diagnostic tests to address challenges for global measles surveillance. Curr Opin Virol. 2020;41:77–84. https://doi.org/10.1016/j.coviro.2020.05.007.
Camilloni B, Stracci F, De Lio MC, Mencacci A, Cenci E, Bozza S. Measles immunity in healthcare workers of an Italian hospital. J Infect Public Health. 2020;13:1123–5. https://doi.org/10.1016/j.jiph.2020.04.001.
Caseris M, Burdet C, Lepeule R, Houhou N, Yeni P, Yazdanpanah Y, et al. Actualité de la rougeole. Rev Med Interne. 2015;36:339–45. https://doi.org/10.1016/j.revmed.2014.10.362.
Christianson B, Sharif-Mohamed F, Heath J, Roddy M, Bahta L, Omar H, et al. Parental attitudes and decisions regarding MMR vaccination during an outbreak of measles among an undervaccinated Somali community in Minnesota. Vaccine. 2020;38:6979–84. https://doi.org/10.1016/j.vaccine.2020.09.022.
Clercq E, Balzarini J, Madej D, Hansske F, Robins MJ. Nucleic acid related compounds. 51: synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin. J Med Chem 1987;30:481–6. https://doi.org/10.1021/jm00386a007
Clercq E, Holy A. Alkyl esters of 3-Adenin-9-yl-2-hydroxypropanoic acid: a new broad-spectrum antiviral agents. J Med Chem 1985;28:282–287
Cottam HB, Kazimierczuk Z, Geary S, McKernan PA, Revankar GR, Robins RK. Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2’-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure. J Med Chem. 1985;28:1461–7. https://doi.org/10.1021/jm00148a015.
Cui A, Zhang Y, Zhu Z, Wang H, Mao N, Song J, et al. Classification of measles cases from 2014 to 2018: implications for progress towards measles elimination in China. Vaccine. 2020;38:3832–8. https://doi.org/10.1016/j.vaccine.2020.03.049.
Cunha BA. Smallpox and measles: historical aspects and clinical differentiation. Infect Dis Clin North Am. 2004;18:79–100. https://doi.org/10.1016/S0891-5520(03)00091-6.
Cutts FT, Henao-Restrepo AM, Olivé JM. Measles elimination: progress and challenges. Vaccine. 1999;17:47–52. https://doi.org/10.1016/S0264-410X(99)00309-6.
Cutts FT, Lessler J, Metcalf CJE. Measles elimination: progress, challenges and implications for rubella control. Expert Rev Vaccines. 2013;12:917–32. https://doi.org/10.1586/14760584.2013.814847.
Danishuddin M, Khan AU. Structure based virtual screening to discover putative drug candidates: necessary considerations and successful case studies. Methods. 2015;71:135–45. https://doi.org/10.1016/j.ymeth.2014.10.019.
De Broucker G, Ssebagereka A, Apolot RR, Aloysius M, Ekirapa Kiracho E, Patenaude B, et al. The economic burden of measles in children under five in Uganda. Vaccine X. 2020;6: https://doi.org/10.1016/j.jvacx.2020.100077.
De Rycker M, Baragaña B, Duce SL, Gilbert IH. Challenges and recent progress in drug discovery for tropical diseases. Nature. 2018;559:498–506. https://doi.org/10.1038/s41586-018-0327-4.
de Toledo-Piza AR, Figueiredo CA, de Oliveira MI, Negri G, Namiyama G, Tonelotto M, et al. The antiviral effect of mollusk mucus on measles virus. Antiviral Res. 2016;134:172–81. https://doi.org/10.1016/j.antiviral.2016.09.005.
Ding Y, Chen W, Lei Y, Mao N, Gao Z, Xu W, et al. Evaluating the population measles susceptibility in Tianjin China. Vaccine. 2020;38:4829–36. https://doi.org/10.1016/j.vaccine.2020.05.053.
Drach JC, Sidwell RW. Antiviral agents. Annu Rep Med Chem. 1981;16:149–59. https://doi.org/10.1016/S0065-7743(08)61282-8.
Dunn JJ, Baldanti F, Puchhammer E, Panning M, Perez O, Harvala H. Measles is back—considerations for laboratory diagnosis. J Clin Virol. 2020;128: https://doi.org/10.1016/j.jcv.2020.104430.
Düx A, Lequime S, Patrono LV, Vrancken B, Boral S, Gogarten J, et al. The history of measles: from a 1912 genome to an antique origin. 2019:1–18. https://doi.org/10.1101/2019.12.29.889667.
Elnagdi MH, Al-Awadi N, Erian AW. Bicyclic 5–6 systems: other four heteroatoms 2:2. Compr Heterocycl Chem II A Rev Lit 1982–1995, vol 7, Elsevier Ltd; 1996, p. 431–88. https://doi.org/10.1016/B978-008096518-5.00156-8.
Forand A, Muchir A, Mougenot N, Sevoz-Couche C, Peccate C, Lemaitre M, et al. Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer-PPMO and AAV-U7 rescues the severe DMD phenotype in mice. Mol Ther Methods Clin Dev. 2020;17:695–708. https://doi.org/10.1016/j.omtm.2020.03.011.
Fragkou PC, Thomas K, Sympardi S, Liatsos GD, Pirounaki M, Sambatakou H, et al. Clinical characteristics and outcomes of measles outbreak in adults: a multicenter retrospective observational study of 93 hospitalized adults in Greece. J Clin Virol. 2020;131: https://doi.org/10.1016/j.jcv.2020.104608.
Fukuhara H, Mwaba MH, Maenaka K. Structural characteristics of measles virus entry. Curr Opin Virol. 2020;41:52–8. https://doi.org/10.1016/j.coviro.2020.04.002.
Ganeshpurkar A, Gutti G, Singh SK. Polymerases and their emerging roles in antiviral therapy. Viral Polym. 2019:1–42. https://doi.org/10.1016/B978-0-12-815422-9.00001-2.
Goodson JL, Seward JF. Measles 50 years after use of measles vaccine. Infect Dis Clin North Am. 2015;29:725–43. https://doi.org/10.1016/j.idc.2015.08.001.
Griffin DE. Measles virus persistence and its consequences. Curr Opin Virol. 2020;41:46–51. https://doi.org/10.1016/j.coviro.2020.03.003.
Griffin DE. Measles immunity and immunosuppression. Curr Opin Virol. 2021;46:9–14. https://doi.org/10.1016/j.coviro.2020.08.002.
Griffith BC, Ulrich AK, Becker AB, Nederhoff D, Koch B, Awan FA, et al. Does education about local vaccination rates and the importance of herd immunity change US parents’ concern about measles? Vaccine. 2020. https://doi.org/10.1016/j.vaccine.2020.09.076.
Gururangan S, Stevens RF, Morris DJ. Ribavirin response in measles pneumonia. J Infect. 1990;20:219–21. https://doi.org/10.1016/0163-4453(90)91094-T.
Guseva S, Milles S, Jensen MR, Schoehn G, Ruigrok RW, Blackledge M. Structure, dynamics and phase separation of measles virus RNA replication machinery. Curr Opin Virol. 2020;41:59–67. https://doi.org/10.1016/j.coviro.2020.05.006.
Harrison C. Infectious disease: small molecule combats measles virus. Nat Rev Drug Discov. 2014;13:416–7. https://doi.org/10.1038/nrd4343.
Hashiguchu T, Fukuda Y, Matsuoda R, Kuroda D, Kubota M, Shirogane Y, et al. Structure of the prefusion form of measles virus fusion protein in complex with inhibitors. PNAS. 2018;115:2496–501. https://doi.org/10.1073/pnas.1718957115.
Herdewijn P, Balzarini J, De Clercq E, Vanderhaeghe H. Resolution of aristeromycin enantiomers. J Med Chem. 1985;28:1385–6. https://doi.org/10.1021/jm00148a002.
Holzmann H, Hengel H, Tenbusch M, Doerr HW. Eradication of measles: remaining challenges. Med Microbiol Immunol. 2016;205:201–8. https://doi.org/10.1007/s00430-016-0451-4.
Hotez PJ, Nuzhath T, Colwell B. Combating vaccine hesitancy and other 21st century social determinants in the global fight against measles. Curr Opin Virol. 2020;41:1–7. https://doi.org/10.1016/j.coviro.2020.01.001.
Hussain A, Ali S, Ahmed M, Hussain S. The anti-vaccination movement: a regression in modern medicine. Cureus. 2018;10. https://doi.org/10.7759/cureus.2919.
Hydrolase MIS, Prisbe EJ, Madhavan B, Mcgee DPC, Rydzewski RM, Boehme R, et al. Synthesis and antiviral evaluation of g’ -substituted aristeromycins: potential. 1988:1798–804.
Kennedy RB, Ovsyannikova IG, Palese P, Poland GA. Current challenges in vaccinology. Front Immunol. 2020;11:1–18. https://doi.org/10.3389/fimmu.2020.01181.
Kitazato K, Wang Y, Kobayashi N. Viral infectious disease and natural products with antiviral activity. Drug Discov Ther. 2007;1:14–22.
Kobayashi A, Shimada T, Tanaka-Taya K, Kanai M, Okuno H, Kinoshita M, et al. Epidemiology of a workplace measles outbreak dominated by modified measles cases at Kansai international airport, Japan, during august–september 2016. Vaccine. 2020;38:4996–5001. https://doi.org/10.1016/j.vaccine.2020.05.067.
Kurokawa M, Ochiai H, Nagasaka K, Neki M, Xu H, Kadota S, et al. Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res. 1993;22:175–88. https://doi.org/10.1016/0166-3542(93)90094-Y.
Lage OM, Ramos MC, Calisto R, Almeida E, Vasconcelos V, Vicente F. Current screening methodologies in drug discovery for selected human diseases. Mar Drugs. 2018;16:1–31. https://doi.org/10.3390/md16080279.
Laksono BM, de Vries RD, Duprex WP, de Swart RL. Measles pathogenesis, immune suppression and animal models. Curr Opin Virol. 2020;41:31–7. https://doi.org/10.1016/j.coviro.2020.03.002.
Lancella L, Di Camillo C, Vittucci AC, Boccuzzi E, Bozzola E, Villani A. Measles lessons in an anti-vaccination era: Public health is a social duty, not a political option. Ital J Pediatr. 2017;43:1–4. https://doi.org/10.1186/s13052-017-0420-6.
Lee YC, Lee YH, Lu CW, Cheng SY, Yang KC, Huang KC. Measles immunity gaps in an era of high vaccination coverage: A serology study from Taiwan. Travel Med Infect Dis. 2020;36: https://doi.org/10.1016/j.tmaid.2020.101804.
Li Q, Zhao Z, Zhou D, Chen Y, Hong W, Cao L, et al. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides. 2011;32:1518–25. https://doi.org/10.1016/j.peptides.2011.05.015.
Lin LT, Hsu WC, Lin CC. Antiviral natural products and herbal medicines. J Tradit Complement Med. 2014;4:24–35. https://doi.org/10.4103/2225-4110.124335.
Ma C, Hao L, Rodewald L, An Q, Wannemuehler KA, Su Q, et al. Risk factors for measles virus infection and susceptibility in persons aged 15 years and older in China: A multi-site case-control study, 2012–2013. Vaccine. 2020;38:3210–7. https://doi.org/10.1016/j.vaccine.2020.03.006.
Magurano F, Baggieri M, Filia A, Del Manso M, Lazzarotto T, Amendola A, et al. Towards measles elimination in Italy: Virological surveillance and genotypes trend (2013–2015). Virus Res. 2017;236:24–9. https://doi.org/10.1016/j.virusres.2017.05.009.
Malonis RJ, Lai JR, Vergnolle O. Peptide-based vaccines: current progress and future challenges. Chem Rev. 2020;120:3210–29. https://doi.org/10.1021/acs.chemrev.9b00472.
McGuigan C, Pathirana RN, Snoeck R, De Andrei G, Clercq E, Balzarini J. Discovery of a new family of inhibitors of human cytomegalovirus (HCMV) based upon lipophilic alkyl furano pyrimidine dideoxy nucleosides: action via a novel non-nucleosidic mechanism. J Med Chem. 2004;47:1847–51. https://doi.org/10.1021/jm030857h.
WHO 2019. https://www.who.int/news-room/fact-sheets/detail/measles. Accessed 13 Nov 2020.
CDC 2020. History of Measles. https://www.cdc.gov/measles/about/history.html. Accessed 13 Nov 2020.
Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol. 2006;4:900–8. https://doi.org/10.1038/nrmicro1550.
Munier-Lehmann H, Lucas-hourani M, Guillou S, Helynck O, Zanghi G, Noel A, et al. Original 2 – (3-Alkoxy – 1 H – pyrazol-1-yl)pyrimidine Derivatives as Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH). J Med. 2015;58:860–77. https://doi.org/10.1021/jm501446r.
Nakao A, Suzuki H, Ueno H, Iwasaki H, Setsuta T, Kashima A, et al. Discovery and structural analyses of S-adenosyl-l-homocysteine hydrolase inhibitors based on non-adenosine analogs. Bioorganic Med Chem. 2015;23:4952–69. https://doi.org/10.1016/j.bmc.2015.05.018.
Naniche D. Human immunology of measles virus infection. Curr Top Microbiol Immunol. 2009;330:151–71. https://doi.org/10.1007/978-3-540-70617-5_8.
Navaratnarajah CK, Miest TS, Carfi A, Cattaneo R. Targeted entry of enveloped viruses: Measles and herpes simplex virus i. Curr Opin Virol. 2012;2:43–9. https://doi.org/10.1016/j.coviro.2011.12.002.
Ndungu JM, Krumm SA, Yan D, Arrendale RF, Reddy GP, Evers T, et al. Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: Synthesis, structure-activity relationships, and pharmacokinetics. J Med Chem. 2012;55:4220–30. https://doi.org/10.1021/jm201699w.
Niedermeier S, Singethan K, Rohrer SG, Matz M, Kossner M, Diederich S, et al. A small-molecule inhibitor of Nipah virus envelope protein-mediated membrane fusion. J Med Chem. 2009;52:4257–65. https://doi.org/10.1021/jm900411s.
Oehler RL. On measles, vaccination, social media activism, and how to win back our role as our patients’ best advocates. Clin Infect Dis. 2020;70:338–40. https://doi.org/10.1093/cid/ciz656.
Ovsyannikova IG, Poland GA. Vaccinomics: Current findings, challenges and novel approaches for vaccine development. AAPS J. 2011;13:438–44. https://doi.org/10.1208/s12248-011-9281-x.
Parker ME, Chabot S, Ward BJ, Johns T. Traditional dietary additives of the Maasai are antiviral against the measles virus. J Ethnopharmacol. 2007;114:146–52. https://doi.org/10.1016/j.jep.2007.06.011.
Paterson BJ, Kirk MD, Cameron AS, D’este C, Durrheim DN. Historical data and modern methods reveal insights in measles epidemiology: a retrospective closed cohort study. BMJ Open. 2013;3:1–10. https://doi.org/10.1136/bmjopen-2012-002033.
Patil SD, Schneller SW, Hosoya M, Snoeck R, Andrei G, Balzarini J, et al. The synthesis and antiviral properties of (.+-.)-5’-noraristeromycin and related purine carbocyclic nucleosides: a new lead for anti-human cytomegalovirus agent design. J Med Chem. 1992;35:3372–7. https://doi.org/10.1021/jm00096a012.
Paules CI, Marston HD, Fauci AS. Measles in 2019—going backward. N Engl J Med. 2019;380:2185–7. https://doi.org/10.1056/NEJMp1905099.
Peña-Rey I, Martínez de Aragón V, Mosquera M, de Ory F, Echevarría JE. Measles risk groups in Spain: implications for the European measles-elimination target. Vaccine. 2009;27:3927–34. https://doi.org/10.1016/j.vaccine.2009.04.024.
Petrie CR, Cottam HB, McKernan PA, Robins RK, Revankar GR. Synthesis and biological activity of 6-azacadeguomycin and certain 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides. J Med Chem. 1985;28:1010–6. https://doi.org/10.1021/jm00146a007.
Petrie CR, Revankar GR, Dailey NK, George RD, McKernan PA, Hamill RL, et al. Synthesis and biological activity of certain nucleoside and nucleotide derivatives of pyrazofurin. J Med Chem. 1986;29:268–78. https://doi.org/10.1021/jm00152a016.
Plemper RK. Measles resurgence and drug development. Curr Opin Virol. 2020;41:8–17. https://doi.org/10.1016/j.coviro.2020.02.007.
Plemper RK, Doyle J, Sun A, Prussia A, Cheng L, Rota PA, et al. Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother. 2005;49:3755–61. https://doi.org/10.1128/AAC.49.9.3755-3761.2005.
Poland GA, Kennedy RB, Ovsyannikova IG. Vaccinomics and personalized vaccinology: Is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog. 2011;7. https://doi.org/10.1371/journal.ppat.1002344.
Prussia AJ, Plemper RK, Snyder JP. Measles virus entry inhibitors: a structural proposal for mechanism of action and the development of resistance. Biochemistry. 2008;47:13573–83. https://doi.org/10.1021/bi801513p.
Pütz MM, Muller CP. The rationale of a peptide-conjugate vaccine against measles. Vaccine. 2003;21:663–6. https://doi.org/10.1016/S0264-410X(02)00576-5.
Roeder P, Mariner J, Kock R. Rinderpest: the veterinary perspective on eradication. Philos Trans R Soc B Biol Sci. 2013;368:20120139. https://doi.org/10.1098/rstb.2012.0139.
Rybicki EP. Plant-produced vaccines: promise and reality. Drug Discov Today. 2009;14:16–24. https://doi.org/10.1016/j.drudis.2008.10.002.
Sánchez-Barrena MJ, Martínez-Ripoll M, Gálvez A, Valdivia E, Maqueda M, Cruz V, et al. Structure of bacteriocin AS-48: from soluble state to membrane bound state. J Mol Biol. 2003;334:541–9. https://doi.org/10.1016/j.mb.2003.09.060.
Santagati NA, Bousquet E, Garozzo A, Prezza O, Spadaro A. Synthesis and anti-measles virus activity of new isoquinolin-4-one derivatives. Farm. 2003;58:1217–25. https://doi.org/10.1016/j.farmac.2003.07.003.
Sarkar D, Julkunen I, Bergha H, Fisher PB, Vainionpa R. The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines. 2006;8:2138–44. https://doi.org/10.1016/j.micinf.2006.04.005.
Schneller SW, Thompson RD, Cory JG, Olsson RA, De Clercq E, Kim I, et al. Biological activity and isomer of formycin. J Med Chem. 1984a;27:924–8.
Schneller SW, Luo JK, Hosmane RS, De Clercq E, Stoeckler JD, Agarwal KC, et al. Synthesis and biological evaluation of 6-amino-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (3,7-dideazaguanine). J Med Chem. 1984b;27:1737–9. https://doi.org/10.1021/jm00378a037.
Schober T. Effects of a measles outbreak on vaccination uptake. Econ Hum Biol. 2020;38: https://doi.org/10.1016/j.ehb.2020.100871.
Shaban MAE. The chemistry of C-Nucleosides and their analogs II: C-Nucleosides of condensed heterocyclic bases. Adv Heterocycl Chem. 1997;70:163–337. https://doi.org/10.1016/s0065-2725(08)60931-9.
Shaffer JA, Bellini WJ, Rota PA. The C protein of measles virus inhibits the type I interferon response. Virology. 2003;315:389–97. https://doi.org/10.1016/S0042-6822(03)00537-3.
Shanks GD, Hu Z, Waller M, Lee SE, Terfa D, Howard A, et al. Measles epidemics of variable lethality in the early 20th century. Am J Epidemiol. 2014;179:413–22. https://doi.org/10.1093/aje/kwt282.
Shrivastava SRBL, Shrivastava PS, Ramasamy J. Measles in India: Challenges and recent developments. Afr J Disabil. 2015;5. https://doi.org/10.3402/iee.v5.27784.
Shuto S, Obara T, Toriya M, Hosoya M, Snoeck R, Andrei G. New neplanocin analogues 1: synthesis of B’ -Modified neplanocin a derivatives as broad-spectrum antiviral agents. 1992:324–31.
Sibeudu FT, Onwujekwe OE, Okoronkwo IL. Cost analysis of supplemental immunization activities to deliver measles immunization to children in Anambra state, south-east Nigeria. Vaccine. 2020;38:5947–54. https://doi.org/10.1016/j.vaccine.2020.06.072.
Singh J, Sharma D, Kumar G, Sharma NR. Microbial bioprospecting for sustainable development. Microb Bioprospecting Sustain Dev 2018:1–397. https://doi.org/10.1007/978-981-13-0053-0.
Singha UK, Miller MB, Nes CR, Anyatonwu H, Lecordier L, Patkar P, et al. Discovery of an ergosterol-signaling factor that regulates Trypanosoma brucei growth. J Lipid Res. 2015;56. https://doi.org/10.1194/jlr.M054643.
Sleeman K, Stein DA, Tamin A, Reddish M, Iversen PL, Rota PA. Inhibition of measles virus infections in cell cultures by peptide-conjugated morpholino oligomers. Virus Res. 2009;140:49–56. https://doi.org/10.1016/j.virusres.2008.10.018.
Spika JS, Wassilak S, Pebody R, Lipskaya G, Deshevoi S, Güriş D, et al. Measles and rubella in the World Health Organization European region: diversity creates challenges. J Infect Dis. 2003;187:191–7. https://doi.org/10.1086/368336.
Stallcup KC, Raine CS, Fields BN. Cytochalasin B inhibits the maturation of measles virus. Virology. 1983;124:59–74. https://doi.org/10.1016/0042-6822(83)90290-8.
Stern AM, Markel H. The history of vaccines and immunization: Familiar patterns, new challenges if we could match the enormous scientific strides of the twentieth century with the political and economic investments of the nineteenth, the world’s citizens might be much heal. Health Aff. 2005;24:611–21. https://doi.org/10.1377/hlthaff.24.3.611.
Sun A, Prussia A, Zhan W, Murray EE, Doyle J, Cheng L, et al. Nonpeptide inhibitors of measles virus entry. 2006:5080–92.
Sun A, Chandrakumar N, Yoon J, Plemper RK, Snyder JP. Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: synthesis and in vitro evaluation. Bioorg Med Chem Lett. 2007;17:5199–203. https://doi.org/10.1016/j.bmcl.2007.06.084.
Sun A, Yoon JJ, Yin Y, Prussia A, Yang Y, Min J, et al. Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex. J Med Chem. 2008;51:3731–41. https://doi.org/10.1021/jm701239a.
Sundaram ME, Guterman LB, Omer SB. The true cost of measles outbreaks during the postelimination era. JAMA. 2019;321:1155. https://doi.org/10.1001/jama.2019.1506.
Swallow DL. Antiviral agents. Prog Drug Res. 1978;22:267–326.
Takayama I, Sato H, Watanabe A, Omi-Furutani M, Sugai A, Kanki K, et al. The nucleocapsid protein of measles virus blocks host interferon response. Virology. 2012;424:45–55. https://doi.org/10.1016/j.virol.2011.12.011.
Terao-muto Y, Yoneda M, Seki T, Watanabe A, Tsukiyama-kohara K, Fujita K, et al. Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAM-negative cell lines. Antiviral Res. 2008;80:370–6. https://doi.org/10.1016/j.antiviral.2008.08.006.
Trottier C, Chabot S, Mann KK, Colombo M, Chatterjee A, Miller WH, et al. Retinoids inhibit measles virus in vitro via nuclear retinoid receptor signaling pathways. Antiviral Res. 2008;80:45–53. https://doi.org/10.1016/j.antiviral.2008.04.003.
Turner MA, Yang X, Yin D, Kuczera K, Borchardt RT, Howell PL. Structure and function of S-adenosylhomocysteine hydrolase. Cell Biochem Biophys. 2000;33:101–25. https://doi.org/10.1385/CBB:33:2:101.
Ugarkar BG, Cottam HB, Mckernan PA, Robins RK, Revankar GR. Synthesis and antiviral/antitumor activities of certain. 1984;1026–1030
Vink JP, Snell LB, Bernard K, Mitchell H, Heathcock RT, Cordery R, et al. Mapping a nosocomial outbreak of measles, coinciding with a period of sustained transmission in South London in 2018. J Hosp Infect. 2020;105:747–51. https://doi.org/10.1016/j.jhin.2020.06.004.
Wang SA, Ko Y, Zeng J, Geng Y, Ren D, Ogasawara Y, et al. Identification of the formycin A biosynthetic gene cluster from streptomyces kaniharaensis illustrates the interplay between biological pyrazolopyrimidine formation and de novo purine biosynthesis. J Am Chem Soc. 2019;141:6127–31. https://doi.org/10.1021/jacs.9b00241.
Webster DE, Thomas MC, Huang Z, Wesselingh SL. The development of a plant-based vaccine for measles. Vaccine. 2005;23:1859–65. https://doi.org/10.1016/j.vaccine.2004.11.018.
White LK, Yoon J, Lee JK, Sun A, Du Y, Fu H, et al. Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. 2007;51:2293–303. https://doi.org/10.1128/AAC.00289-07.
Wong AH, Ho YII, Tang KPS, Lai RWM. Comparison of CaptiaTM Measles IgG Assay with Vidas® Measles IgG Assay for determination of immune protection status against measles virus. J Clin Virol. 2020;127: https://doi.org/10.1016/j.jcv.2020.104342.
Xu L, Chen J, Zhan Z, Chen T, Liu W, Qian J, et al. Evaluating the effectiveness of national measles elimination action in mainland China during 2004–2016: A multi-site interrupted time-series study. Vaccine. 2020;38:4440–7. https://doi.org/10.1016/j.vaccine.2020.04.053.
Yoon J, Krumm SA, Ndungu JM, Hoffman V, Bankamp B, Rota PA, et al. Target analysis of the experimental measles therapeutic AS-136A. Antimicrob Agents Chemother. 2009;53:3860–70. https://doi.org/10.1128/AAC.00503-09.
Zhang N, Chen HM, Sood R, Kalicharran K, Fattom AI, Naso RB, et al. In vitro inhibition of the measles virus by novel ring-expanded (‘fat’) nucleoside analogues containing the imidazo[4,5-e][1,3]diazepine ring system. Bioorganic Med Chem Lett. 2002;12:3391–4. https://doi.org/10.1016/S0960-894X(02)00762-X.
Acknowledgements
The authors thank the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brazil (CAPES), Fundação de Amparo à Pesquisa do Estado de Alagoas (FAPEAL), and the National Council for Scientific and Technological Development (CNPq)—Brazil for their support to the Brazilian Post-Graduate Programs. Finally, we would like to thank the BioRender (https://biorender.com/) for providing figures to ellaborate our biological schemes.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
None.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nascimento, I.J.S., Santos-Júnior, P.F.S., Silva-Júnior, E.F. (2021). Brief Introduction of Measles Virus and Its Therapeutic Strategies. In: Ahmad, S.I. (eds) Human Viruses: Diseases, Treatments and Vaccines . Springer, Cham. https://doi.org/10.1007/978-3-030-71165-8_23
Download citation
DOI: https://doi.org/10.1007/978-3-030-71165-8_23
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71164-1
Online ISBN: 978-3-030-71165-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)